Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-MG: Amifampridine and Pyridostigmine in Myasthenia Gravis
NCT05919407Phase 3Unknown
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of amifampridine in myasthenia gravis (MG), sponsored by Leiden University Medical Center. Status: unknown.
02
Drugs
amifampridine
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05919407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05919407.